ACRS – aclaris therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $15.00 price target on the stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Aclaris Therapeutics to Participate in Two March Healthcare Conferences [Yahoo! Finance]
Form PRE 14A Aclaris Therapeutics, For: Jun 05
Form 4 Aclaris Therapeutics, For: Apr 01 Filed by: Walker Neal
Form EFFECT Aclaris Therapeutics,
Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Monahan Joseph
Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Walker Neal
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.